The Executive Summary: Emerging Cancer Vaccine Market, 2nd Edition

Containing a snapshot of the overall market analysis, each Executive Summary provides a description of the scope and methodology used in the report; a summary of results including market size and market growth; a sampling of charts and graphs when available; and a brief look at the trends shaping the market.

The report from which this Executive Summary is compiled is Emerging Cancer Vaccine Market, 2nd Edition, and the full study abstract is as follows:

Propelled by advances in molecular biology, the cancer vaccine industry is poised for unprecedented growth. This second edition of Kalorama’s groundbreaking 2003 study completely updates the market data and reviews the technological, clinical, and business trends that have shaped and reshaped this emerging field.

Specific segments covered in the report include:

• Cervical cancer,
• Colorectal cancer,
• Lung cancer,
• Lymphoma,
• Melanoma,
• Prostate cancer, and
• Other cancers for which vaccines are in development.

Each market segment provides an overview, descriptions of products available and in development, market estimates and forecasts for 2007-2012 by product, and competitive analysis of leading developers, including forecasted market share for 2012. The report also includes statistical information on cancers by type worldwide and in the United States. Profiles of the following developers and marketers are also included:

• Advaxis, Inc.
• Antigenics, Inc.
• Aphton Corporation
• AVAX Technologies, Inc.
• Biomira, Inc.
• Biovest International, Inc.
• Cell Genesys, Inc.
• Dendreon Corporation
• Favrille, Inc.
• GenMax Corporation
• Genitope Corporation
• Genzyme
• Geron Corporation
• GlaxoSmithKline
• IDM
• Intracel
• Large Scale Biology Corporation
• Medarex, Inc.
• MedImmune, Inc.
• Merck & Company, Inc.
• Northwest Biotherapeutics
• Oxford Biomedica, Plc
• Pharmexa Group
• Progenics Pharmaceuticals, Inc.
• Therion Biologics Corporation
• Vical, Inc.
• YM Biosciences, Inc.